Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - Jasper Therapeutics is focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][6] - The company reported a net loss of $18.7 million for the fiscal quarter ended September 30, 2025, with a basic and diluted net loss per share of $1.13 [5][9] - Jasper has successfully completed a $30 million underwritten offering of common stock and warrants, extending its cash runway through the first half of 2026 [5] Financial Results - For the three months ended September 30, 2025, research and development expenses were $14.4 million, while general and administrative expenses were $4.8 million [5][9] - Cash and cash equivalents as of September 30, 2025, totaled $50.9 million, down from $71.6 million as of December 31, 2024 [10] - Total operating expenses for the third quarter of 2025 were $19.2 million, compared to $19.9 million for the same period in 2024 [9] Clinical Development - The ongoing investigation into anomalous efficacy results from the BEACON study is nearing completion, with no evidence of drug substance or drug product issues identified [2][5] - Initial data from the ETESIAN study in allergic asthma is expected to be reported in the fourth quarter of 2025, along with updated data from CSU and CIndU patients in the open-label extension study [2][5] - The company plans to commence the Phase 2b CSU study in mid-2026, pending the completion of dose selection based on additional data from ongoing studies [5][6]